Skip to main content
TipRanks
Go Ultimate75% OFF

Emergent Biosolutions (EBS) AI Stock Analysis

1,363 Followers
EBS

Emergent Biosolutions

(NYSE:EBS)

Select Model
Rating:52Neutral
Price Target:$6.00â–²(3.63% Upside)
Action:reiterated
Date:11/05/26

The score reflects a tug-of-war between strong recent cash generation and improving cost actions (including gross margin guidance improvement and restructuring savings) versus weak profitability and declining revenue, elevated leverage, and bearish technical signals with the stock trading below all key moving averages.

Positive Factors
Strong cash generationStrong year-to-date EBITDA and operating cash flow provide internal funding for operations, debt service and selected growth initiatives. This improves resilience during uneven government delivery cycles, although the durability of cash conversion depends on improving underlying earnings quality.
Negative Factors
Declining revenue and delivery dependenceLarge year-over-year revenue declines and expected MCM contraction show that sales remain highly dependent on the timing of government and international deliveries. This creates uneven utilization and makes near-term operating performance less predictable even when contracts remain strategically valuable.

Emergent Biosolutions (EBS) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%EBS-42.79%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$297.69M
Dividend Yield
―
Average Volume (3M)
1.13M
Price to Earnings (P/E)
-1.1
Beta (1Y)
1.94
Revenue Growth
-17.72%
EPS Growth
-456.60%
Country
US
Employees
900
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Emergent Biosolutions Business Overview & Revenue Model

Company Description

Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and natu...

How the Company Makes Money

EBS generates revenue primarily through (1) product sales and procurement contracts and (2) contract services. Product-related revenue is largely driven by medical countermeasures purchased under government procurement and preparedness programs (e.g....

Emergent Biosolutions Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|% Change Since:-10.09%|Next Earnings Date:Mar 03, 2027
Earnings Call SentimentPositive

The call was generally positive, emphasizing strong year-to-date cash generation, debt reduction, cost-management actions, international MCM diversification, continued naloxone market leadership and progress on growth programs. These positives were tempered by a substantial year-over-year third-quarter revenue decline, negative quarterly adjusted EBITDA, competitive pricing and volume pressure in naloxone, an expected full-year MCM revenue decline and uncertainty around the timing of government and international deliveries.

Positive Updates

Third-Quarter Revenue Met Guidance
Third-quarter revenue was $110 million, within the company's guidance range, bringing year-to-date revenue to $500 million.

Negative Updates

Third-Quarter Revenue Declined Significantly Year-over-Year
Third-quarter revenue was $110 million versus $231 million in the third quarter of 2025. The comparison was primarily influenced by the timing of MCM deliveries, including accelerated deliveries in the second quarter of 2026.

Company Guidance

Emergent now expects full year 2026 total revenues of $600 million to $645 million; MCM revenues are expected to decline versus the prior year based on the timing of remaining international MCM deliveries and U.S. government procurement, while Commercial revenue is currently tracking towards the lower end of the 20% to 25% range of revenue reduction versus 2025. The company expects adjusted gross margin of 45% to 47%, a 300 basis point improvement versus its August guidance, and adjusted EBITDA of $110 million to $140 million, with the upper end of the range consistent with the midpoint of its prior guidance. Restructuring actions are expected to generate approximately $40 million of annualized savings, with the initial impact becoming evident in the fourth quarter of 2026; some orders internationally and with the U.S. government may materialize this year or in the early part of next year.

Emergent Biosolutions Financial Statement Overview

Summary

Fundamentals are mixed: cash flow is a clear strength (TTM operating cash flow about $200M and free cash flow about $188M), but profitability and sales trends are weak (TTM swung back to meaningful losses and revenue declined about 15.7%). Leverage is elevated (debt-to-equity ~1.62), which increases risk if profitability does not stabilize.

Income Statement

28Negative

Balance Sheet

46Neutral

Cash Flow

71Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue649.10M742.90M1.04B1.05B1.12B1.77B
Gross Profit270.00M350.60M375.40M360.00M473.00M793.20M
EBITDA-117.20M237.90M56.60M-43.00M34.00M509.80M
Net Income-260.70M52.60M-190.60M-760.50M-211.60M219.50M
Balance Sheet
Total Assets995.20M1.32B1.39B1.82B3.17B2.96B
Cash, Cash Equivalents and Short-Term Investments175.70M205.40M99.50M111.70M642.60M576.30M
Total Debt507.70M572.10M676.10M860.20M1.43B871.00M
Total Liabilities682.00M796.00M906.90M1.17B1.78B1.35B
Stockholders Equity313.20M522.60M482.80M649.30M1.39B1.61B
Cash Flow
Free Cash Flow188.40M156.80M35.80M-257.90M-149.90M96.10M
Operating Cash Flow200.10M170.60M58.70M-206.30M-34.10M321.10M
Investing Cash Flow-54.00M69.40M125.20M212.30M-381.30M-225.00M
Financing Cash Flow-218.40M-136.60M-190.00M-535.70M481.20M-141.00M

Emergent Biosolutions Technical Analysis

Technical Analysis SentimentNegative
Last Price5.79

Price Trends

50DMA6.50Negative
100DMA6.62Negative
200DMA7.73Negative

Market Momentum

MACD-0.19Positive
RSI38.29Neutral
STOCH22.70Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EBS, the sentiment is Negative. The current price of 5.79 is below the 20-day moving average (MA) of 6.29, below the 50-day MA of 6.50, and below the 200-day MA of 7.73, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 38.29 is Neutral, neither overbought nor oversold. The STOCH value of 22.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EBS.

Emergent Biosolutions Risk Analysis

Emergent Biosolutions disclosed 59 risk factors in its most recent earnings report. Emergent Biosolutions reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We cannot guarantee that our 2025 Share Repurchase Program will be utilized in full, or at all, or that our 2025 Share Repurchase Program will enhance long-term stockholder value.Q4, 2025
2.Divestitures and sales of assets could negatively impact our business, and retained liabilities from businesses or assets that we have sold could adversely affect our financial results.Q4, 2025
3.Changes to tax legislation may adversely affect our business.Q4, 2025

Emergent Biosolutions Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

EBS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AMPHAMPH77Outperform$1.25B13.0512.59%―3.11%-4.26%
CPIXCPIX53Neutral$88.10M1.28202.58%23.57%-39.11%-241.27%
EBSEBS52Neutral$297.69M-1.15-61.33%―-17.72%-456.60%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
EVOEVO50Neutral$580.87M-2.91-25.63%―0.31%-19.37%
SIGASIGA49Neutral$196.88M428.120.42%―-69.60%-99.10%
TLPHTLPH49Neutral$47.07M-3.50-96.70%―-100.00%46.24%

* Healthcare Sector Average

Performance Comparison

0%200%400%EBSTLPHSIGAAMPHEVOCPIXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
EBS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
EBSEmergent Biosolutions5.79-4.31-42.67%
TLPHTalphera, Inc.0.91-0.41-31.36%
SIGASiga Technologies2.74-2.48-47.50%
AMPHAmphastar Pharmaceuticals Inc29.373.3512.87%
EVOEvotec Ag (Adr)1.58-1.38-46.62%
CPIXCumberland Pharmaceuticals Inc.5.884.41299.19%

Emergent Biosolutions Corporate Events

Business Operations and Strategy

Emergent BioSolutions Secures $22.3 Million Anthrax Vaccine Contract Modification

Positive
Nov 4, 2026

On November 4, 2026, Emergent BioSolutions announced a modification valued at up to $22.3 million under an existing U.S. government contract to supply BioThrax anthrax vaccine. The order supports pre-exposure protection for service members across all...

Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing

Emergent BioSolutions Reports Third-Quarter 2026 Results and Restructuring

Negative
Nov 2, 2026

Emergent BioSolutions, a biodefense and medical-countermeasures company with a portfolio spanning naloxone, anthrax and smallpox products, reported third-quarter 2026 results on Nov. 2, 2026. Revenue for the quarter ended Sept. 30 was $110.0 million,...

Business Operations and StrategyExecutive/Board Changes

Emergent BioSolutions Announces CFO Transition Amid Transformation

Neutral
Oct 16, 2026

Emergent BioSolutions announced on October 16, 2026, that longtime chief financial officer Richard S. Lindahl will retire from his role on December 31, 2026, after nearly nine years at the company. He will stay on as a senior executive advisor throug...

Business Operations and StrategyProduct-Related Announcements

Emergent Biosolutions Highlights Global Public Health Countermeasures

Positive
Sep 14, 2026

On September 14, 2026, Emergent BioSolutions’ president and chief executive officer Joseph C. Papa presented at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting the company’s leadership in combating public health threats wor...

Business Operations and StrategyFinancial Disclosures

Emergent BioSolutions Secures New BARDA Anthrax Contract

Positive
Sep 1, 2026

Emergent BioSolutions, a biopharmaceutical company specializing in biodefense and medical countermeasures, has reinforced its position as a key supplier to the U.S. government’s preparedness programs. Its anthrax vaccines CYFENDUS and BioThrax are ap...

Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing

Emergent BioSolutions Announces Restructuring Amid Turnaround Efforts

Negative
Aug 5, 2026

On August 5, 2026, Emergent BioSolutions reported second-quarter 2026 revenue of $234.3 million, up 66% year-on-year, alongside a net loss of $180.2 million driven largely by a $191.3 million non-cash impairment charge, while adjusted net income rose...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026